Publication: In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: Results of the COMPACT Asia-Pacific Study
Issued Date
2010-12-01
Resource Type
ISSN
09248579
Other identifier(s)
2-s2.0-78249250570
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Antimicrobial Agents. Vol.36, No.6 (2010), 501-506
Suggested Citation
K. J. Christiansen, M. Ip, H. B. Ker, M. Mendoza, L. Hsu, P. Kiratisin, A. Chongthaleong, I. S. Redjeki, A. Quintana, R. Flamm, J. Garcia, M. Cassettari, D. Cooper, P. Okolo, I. Morrissey In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: Results of the COMPACT Asia-Pacific Study. International Journal of Antimicrobial Agents. Vol.36, No.6 (2010), 501-506. doi:10.1016/j.ijantimicag.2010.08.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/29440
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: Results of the COMPACT Asia-Pacific Study
Other Contributor(s)
Royal Perth Hospital
Chinese University of Hong Kong
Hospital Raja Permaisuri Bainun
Philippine General Hospital
National University Hospital, Singapore
Mahidol University
King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University
Hasan Sadikin General Hospital
Johnson & Johnson
Janssen-Cilag Asia-Pacific
Pharmaron UK
Chinese University of Hong Kong
Hospital Raja Permaisuri Bainun
Philippine General Hospital
National University Hospital, Singapore
Mahidol University
King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University
Hasan Sadikin General Hospital
Johnson & Johnson
Janssen-Cilag Asia-Pacific
Pharmaron UK
Abstract
The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific region and to assess the reliability of Etest methodology for doripenem minimum inhibitory concentration (MIC) determination against these pathogens. Data from eight countries within the Asia-Pacific region, which collected 1612 bacterial isolates, are presented here. Etest methodology was found to be a reliable method for MIC determination. Doripenem showed in vitro activity similar to or better than meropenem and at least four-fold better than imipenem against Enterobacteriaceae. Against Pseudomonas aeruginosa, doripenem was also the most active of the three carbapenems in vitro. However, in vitro results do not necessarily correlate with clinical outcome. © 2010 Elsevier B.V. and the International Society of Chemotherapy.